Technical Analysis for XOMA - XOMA Corporation

Grade Last Price % Change Price Change
grade B 26.03 0.97% 0.25
XOMA closed up 0.97 percent on Tuesday, November 19, 2019, on 2.2 times normal volume. The bulls were able to push the stock to a new 52-week high. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical XOMA trend table...

Date Alert Name Type % Chg
Shooting Star Candlestick Bearish 0.00%
New 52 Week Closing High Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Doji - Bearish? Reversal 0.00%
New 52 Week High Strength 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Up 5 Days in a Row Strength 0.00%

Older signals for XOMA ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company offers ACEON, an angiotensin converting enzyme inhibitor. Its proprietary products include gevokizumab, a human engineering (HE) antibody to interleukin-1 beta, which is Phase III studies for non-infectious uveitis and Behçet's uveitis; and Phase II studies for inflammatory acne, erosive osteoarthritis of the hand, active non-infectious anterior scleritis, and cardiovascular diseases. The company's proprietary products also comprise XOMA metabolic activating, sensitizing, and antagonizing/deactivating antibodies that are in preclinical stage for diabetes, metabolic disorders, and other orphan indications; XOMA 3AB, a multi-antibody product, which is in Phase I trial for botulism poisoning; and preclinical programs for autoimmune, cardio-metabolic, infectious, inflammatory, ophthalmological, and oncological diseases. In addition, it develops FDC1, a perindopril arginine and amlodipine besylate, which has completed Phase III trial for hypertension; HCD122 and LFA102 programs that are in Phase I and II, and Phase I trials for hematologic tumors, breast and prostate cancers, and other undisclosed diseases; human monoclonal antibodies, which are in preclinical stage for undisclosed disease targets; and therapeutic antibodies that are in Phase II and Phase I trials for non-small cell lung cancer, solid tumors, and multiple myeloma. Further, the company licenses Antibody Discovery Advanced Platform Technologies, ModulX, and OptimX antibody discovery, optimization, and development technologies. It has collaboration agreements with Les Laboratoires Servier; National Institute of Allergy and Infectious Diseases; Takeda Pharmaceutical Company Limited; Novartis AG; Arana Therapeutics Limited; Kaketsuken; AVEO Pharmaceuticals, Inc.; UCB Celltech; and Genentech, Inc. XOMA Corporation was founded in 1981 and is headquartered in Berkeley, California.
Medicine Health Immunology Diabetes Antibodies Solid Tumors Immune System Monoclonal Antibodies Non Small Cell Lung Cancer Antibody Multiple Myeloma Cardiovascular Diseases Hypertension Metabolic Disorders Uveitis Inflammatory Non Infectious Uveitis
Is XOMA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 26.9
52 Week Low 11.02
Average Volume 43,462
200-Day Moving Average 16.7038
50-Day Moving Average 20.0393
20-Day Moving Average 21.934
10-Day Moving Average 24.431
Average True Range 1.0506
ADX 49.07
+DI 41.7086
-DI 4.4153
Chandelier Exit (Long, 3 ATRs ) 23.7482
Chandelier Exit (Short, 3 ATRs ) 20.8532
Upper Bollinger Band 27.2294
Lower Bollinger Band 16.6386
Percent B (%b) 0.89
BandWidth 48.284855
MACD Line 1.8347
MACD Signal Line 1.4116
MACD Histogram 0.4231
Fundamentals Value
Market Cap 197.77 Million
Num Shares 7.6 Million
EPS -6.93
Price-to-Earnings (P/E) Ratio -3.76
Price-to-Sales 13.67
Price-to-Book 0.00
PEG Ratio -0.40
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 27.88
Resistance 3 (R3) 27.96 27.43 27.57
Resistance 2 (R2) 27.43 26.96 27.39 27.46
Resistance 1 (R1) 26.73 26.67 27.08 26.65 27.36
Pivot Point 26.20 26.20 26.38 26.16 26.20
Support 1 (S1) 25.50 25.73 25.85 25.42 24.70
Support 2 (S2) 24.97 25.44 24.93 24.60
Support 3 (S3) 24.27 24.97 24.49
Support 4 (S4) 24.19